Ovarian Cancer
Coverage from the ASCO20 Virtual Scientific Program

Focus on Ovarian Cancer

Featured Content

Pembrolizumab Monotherapy for Advanced Recurrent Ovarian Cancer

Findings from the KEYNOTE-100 trial show that pembrolizumab monotherapy resulted in modest antitumor activity among patients with advanced recurrent ovarian cancer, according to data presented at the ASCO 2020 Annual Meeting (Abstract 6005).

Read Now

Combination Therapy Shows Promise in Certain Recurrent Ovarian Cancer

Mirvetuximab soravtansine (MIRV) in combination with bevacizumab demonstrated an encouraging overall response rate (ORR) with a favorable tolerability profile among recurrent ovarian cancer patients, regardless of platinum sensitivity, particularly in those with tumors that express high levels of folate receptor alpha (FRα). These findings were presented in an oral presentation during the ASCO 2020 Annual Meeting (Abstract 6004).

Read Now

Improving Access to Genetic Testing for Ovarian & Breast Cancer Risk

New findings presented at the ASCO 2020 Annual Meeting suggest that receiving electronic genetic education and results without counseling was not associated with higher levels of distress (Abstract 1506). These results support the use of a genetic testing paradigm providing individualized genetic counseling only for patients with positive test results, according to the study authors

Read Now

Fatigue & Poor Health Status in Long-Term Ovarian Cancer Survivors

Fatigue and other toxicities remain common among long-term survivors (LTS) with ovarian cancer, leading to worsened health status and other side effects. Findings presented at the ASCO 2020 Annual Meeting emphasize the need for survivorship clinics to address these issues (Abstract 12065).

Read Now

PARP Inhibitor Maintenance Therapy for Ovarian Cancer

Findings from the randomized, phase III SOLO2 trial show that maintenance therapy with the PARP inhibitor olaparib improved overall survival by 12.9 months compared with placebo among women with platinum-sensitive relapsed ovarian cancer with BRCA1 or BRCA2. The results were presented during the 2020 ASCO Annual Meeting (Abstract 6002).

Read Now

The Role of Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

A phase II trial demonstrated the safety of hyperthermic intraperitoneal chemotherapy (HIPEC) among patients with ovarian cancer, according to findings presented at the 2020 ASCO Annual Meeting (Abstract 6016). Additional study is required to better understand its potential impact on survival.

Read Now